Rocket Pharmaceuticals secures FDA alignment on pivotal Phase 2 RP-A501 trial with 12-patient efficacy population

Rocket Pharmaceuticals announced FDA alignment to continue enrollment and dosing in the pivotal Phase 2 RP-A501 trial for Danon disease, confirming a 12—patient pivotal population and 12—month co—primary endpoints.Key Highlights:Original SEC Filing: ROCKET PHARMACEUTICALS, INC. [ RCKT ] - 8-K - Sep…